메뉴 건너뛰기
Clinical Advances in Hematology and Oncology
Volumn 5, Issue 4, 2007, Pages
Advances in CML
Author keywords

[No Author keywords available]
Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; BOSUTINIB; BUSULFAN; CRK LIKE PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; INNO 406; INNOVIVE; MERCK 0547; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;
EID: 34249090202     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (10)
References (6)
  • 1
    • 33644877460 scopus 로고    scopus 로고
    • Cooperative German Transplant Study Group. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukamia in the era of imatinib: A retrospective multicentre study
    • Bornhauser M, Kroger N, Schwerdtfeger R, et al; Cooperative German Transplant Study Group. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukamia in the era of imatinib: a retrospective multicentre study. Eur J Haematol. 2006;76:9-17.
    • (2006) Eur J Haematol , vol.76 , pp. 9-17
    • Bornhauser, M.1    Kroger, N.2    Schwerdtfeger, R.3
  • 2
    • 33747154547 scopus 로고    scopus 로고
    • European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiNet
    • Baccarani M, Saglio G, Goldman J, et al; European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiNet. Blood. 2006;108: 1809-1820.
    • (2006) Blood , vol.108 , pp. 1809-1820
    • Baccarani, M.1    Saglio, G.2    Goldman, J.3
  • 3
    • 33845991464 scopus 로고    scopus 로고
    • Durabale responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloprofilerative disorders
    • David M, Cross NC, Burgstaller S, et al. Durabale responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloprofilerative disorders. Blood. 2007;109:61-64.
    • (2007) Blood , vol.109 , pp. 61-64
    • David, M.1    Cross, N.C.2    Burgstaller, S.3
  • 4
    • 33845444046 scopus 로고    scopus 로고
    • IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    • Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006:355:2408-2417.
    • (2006) N Engl J Med , vol.355 , pp. 2408-2417
    • Druker, B.J.1    Guilhot, F.2    O'Brien, S.G.3
  • 5
    • 33745603988 scopus 로고    scopus 로고
    • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    • Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
    • (2006) Blood , vol.108 , pp. 28-37
    • Hughes, T.1    Deininger, M.2    Hochhaus, A.3
  • 6
    • 33845982249 scopus 로고    scopus 로고
    • Targeting cancers with tyrosine kinase inhibitors: Lessons from chronic myeloid leukaemia
    • Mughal TI, Goldman JM. Targeting cancers with tyrosine kinase inhibitors: lessons from chronic myeloid leukaemia. Clin Med. 2006;6:526-528.
    • (2006) Clin Med , vol.6 , pp. 526-528
    • Mughal, T.I.1    Goldman, J.M.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.